Marion Gardner, MD
Family Medicine · North Plains, ORNPI 1740382480
Payments from drug & device makers
Across 149 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$421
- AstraZeneca$360
- AbbVie$243
- Johnson & Johnson$223
- Pfizer$183
- Exact Sciences$107
- plus $937 from 20 others
What the payments were for
- Food & beverage$2,474100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 26 | $421 |
| AstraZeneca | 16 | $360 |
| AbbVie(2 entities) | 15 | $243 |
| Johnson & Johnson | 11 | $223 |
| Pfizer | 16 | $183 |
| Exact Sciences | 6 | $107 |
| E.r. Squibb & Sons, L.L.C. | 5 | $89 |
| Novo Nordisk | 5 | $81 |
| GSK | 5 | $80 |
| Daiichi Sankyo Inc. | 5 | $77 |
| Astellas Pharma US Inc | 4 | $70 |
| Novartis | 4 | $66 |
| Merck | 4 | $66 |
| Boehringer Ingelheim | 5 | $62 |
| Amarin Pharma, Inc. | 2 | $47 |
| Vertical Pharmaceuticals, LLC | 2 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $36 |
| Organon | 3 | $35 |
| Lilly USA, LLC | 2 | $31 |
| Boston Scientific | 1 | $28 |
| Smith+Nephew | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,474 in reported general payments places this provider in the 90th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $108,341 |
| OzempicSemaglutide | 46 | $58,785 |
| JardianceEmpagliflozin | 35 | $48,089 |
| MyrbetriqMirabegron | 56 | $36,081 |
| TrulicityDulaglutide | 26 | $32,972 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $24,781 |
| Repatha SureclickEvolocumab | 20 | $23,018 |
| XareltoRivaroxaban | 19 | $21,237 |
| FarxigaDapagliflozin Propanediol | 18 | $18,207 |
| Spiriva HandihalerTiotropium Bromide | 13 | $16,723 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $14,411 |
| QuliptaAtogepant | 13 | $13,795 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $13,480 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $10,615 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $8,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $183 | $108,34191 claims |
| Novo NordiskOzempic | $81 | $58,78546 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $62 | $58,70453 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $80 | $39,19249 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $360 | $36,35643 claims |
| Astellas Pharma US IncMyrbetriq | $70 | $36,08156 claims |
| Lilly USA, LLCTrulicity | $31 | $32,97226 claims |
| Johnson & JohnsonXarelto | $223 | $21,23719 claims |
| AbbVieQulipta | $243 | $13,79513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in North Plains
- John DelgadoAshland$4.3M
- John MickelsonLincoln City$2.1M
- Subramaniam SeetharamanMilwaukie$1.8M
- Eden MillerBend$1.7M
- Maureen MaysPortland$491K
- Thomas TurkRoseburg$434K
- Anil RajaniHood River$325K
- Patricia BuchananEugene$239K
- Keith KlattAstoria$166K
- Stephen NelsonMedford$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.